PL3783027T3 - Sposób i kompozycje do indukowania różnicowania komórek supresorowych pochodzących ze szpiku do leczenia nowotworu złośliwego - Google Patents

Sposób i kompozycje do indukowania różnicowania komórek supresorowych pochodzących ze szpiku do leczenia nowotworu złośliwego

Info

Publication number
PL3783027T3
PL3783027T3 PL20177260.5T PL20177260T PL3783027T3 PL 3783027 T3 PL3783027 T3 PL 3783027T3 PL 20177260 T PL20177260 T PL 20177260T PL 3783027 T3 PL3783027 T3 PL 3783027T3
Authority
PL
Poland
Prior art keywords
compositions
treat cancer
inducing differentiation
derived suppressor
suppressor cell
Prior art date
Application number
PL20177260.5T
Other languages
English (en)
Polish (pl)
Inventor
Nicolas Poirier
Bernard Vanhove
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51868772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3783027(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of PL3783027T3 publication Critical patent/PL3783027T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
PL20177260.5T 2014-10-24 2015-10-21 Sposób i kompozycje do indukowania różnicowania komórek supresorowych pochodzących ze szpiku do leczenia nowotworu złośliwego PL3783027T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14190370.8A EP3012271A1 (en) 2014-10-24 2014-10-24 Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases

Publications (1)

Publication Number Publication Date
PL3783027T3 true PL3783027T3 (pl) 2026-04-20

Family

ID=51868772

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20177260.5T PL3783027T3 (pl) 2014-10-24 2015-10-21 Sposób i kompozycje do indukowania różnicowania komórek supresorowych pochodzących ze szpiku do leczenia nowotworu złośliwego
PL15794641T PL3209691T3 (pl) 2014-10-24 2015-10-21 Kompozycje do indukowania różnicowania komórek supresorowych pochodzących ze szpiku do leczenia chorób nowotworowych i zakaźnych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL15794641T PL3209691T3 (pl) 2014-10-24 2015-10-21 Kompozycje do indukowania różnicowania komórek supresorowych pochodzących ze szpiku do leczenia chorób nowotworowych i zakaźnych

Country Status (9)

Country Link
US (3) US20170247464A1 (enExample)
EP (4) EP3012271A1 (enExample)
JP (3) JP6918279B2 (enExample)
CA (1) CA2964203C (enExample)
DK (2) DK3783027T3 (enExample)
ES (2) ES3060595T3 (enExample)
HU (1) HUE050318T2 (enExample)
PL (2) PL3783027T3 (enExample)
WO (1) WO2016063233A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
WO2017027422A1 (en) 2015-08-07 2017-02-16 Alexo Therapeutics Inc. Constructs having a sirp-alpha domain or variant thereof
ES2894335T5 (es) 2015-08-26 2024-06-27 Univ Leland Stanford Junior Reducción mejorada de células objetivo con bloqueo de CD47 y un agonista coestimulador inmune
WO2017068164A1 (en) * 2015-10-21 2017-04-27 Ose Immunotherapeutics Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
HRP20241316T1 (hr) 2016-04-14 2024-12-20 Ose Immunotherapeutics Nova anti-sirpa antitijela i njihove terapijske primjene
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
WO2018008470A1 (ja) * 2016-07-05 2018-01-11 国立大学法人神戸大学 抗腫瘍剤
JOP20190009A1 (ar) * 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
CN110325549B (zh) 2016-12-09 2024-03-08 艾利妥 抗SIRPα抗体及其使用方法
WO2018127918A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A sirp alpha-cd70 fusion protein and methods of use thereof
RU2769513C2 (ru) 2017-01-05 2022-04-01 Кахр Медикал Лтд. Слитый белок pd1-4-1bbl и способы его применения
PL3565828T3 (pl) 2017-01-05 2022-04-04 Kahr Medical Ltd. Białko fuzyjne SIRP1 ALFA-41BBL i sposoby jego zastosowania
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
EP3570846A4 (en) * 2017-01-18 2020-10-21 Nant Holdings IP LLC MODULATION OF SUSCEPTIBILITY OF TUMOR CELLS
WO2018152340A1 (en) * 2017-02-15 2018-08-23 The Regents Of The University Of California Compositions and methods for activating nk cells
US11401329B2 (en) 2017-08-02 2022-08-02 Phanes Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
US11713356B2 (en) 2017-10-13 2023-08-01 Ose Immunotherapeutics Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer
WO2019175218A1 (en) 2018-03-13 2019-09-19 Ose Immunotherapeutics Use of anti-human sirpa v1 antibodies and method for producing anti-sirpa v1 antibodies
EP3768314A4 (en) 2018-03-21 2022-01-05 ALX Oncology Inc. ANTIBODIES AGAINST ALPHA SIGNAL REGULATING PROTEIN AND METHODS OF USE
MX2020011828A (es) 2018-05-25 2021-02-09 Alector Llc Anticuerpos anti proteina alfa reguladora de se?ales (sirpa) y metodos de uso de los mismos.
US11759485B2 (en) 2018-06-14 2023-09-19 Meiji Co., Ltd. Composition for enhancing immune checkpoint blockade therapy
CA3104778A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. Pd1-4-1bbl variant fusion protein and methods of use thereof
KR102945860B1 (ko) 2018-07-11 2026-03-31 카 메디컬 리미티드 SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
TW202028237A (zh) 2018-09-27 2020-08-01 美商西建公司 SIRPα結合蛋白及其使用方法
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CA3116327A1 (en) * 2018-10-19 2020-04-23 Ohio State Innovation Foundation Nano-engineered therapeutic stealth cells
KR20220044904A (ko) 2019-05-31 2022-04-12 알렉소 온콜로지 인크. 면역 관문 억제제와 병용하는 sirp 알파 fc 융합으로 암을 치료하는 방법
US20200400662A1 (en) 2019-06-07 2020-12-24 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
CN114845710A (zh) 2019-11-27 2022-08-02 Alx肿瘤生物技术公司 用于治疗癌症的组合疗法
JP2023528341A (ja) 2020-06-01 2023-07-04 エーエルエックス オンコロジー インコーポレイテッド 低メチル化剤を含むがんを治療するための併用療法
CN111808800B (zh) * 2020-07-20 2022-08-26 中南大学湘雅二医院 一种体外诱导免疫抑制性髓系抑制细胞及其制备和应用
US20220196651A1 (en) 2020-12-06 2022-06-23 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
BR112023022774A2 (pt) 2021-05-13 2024-01-02 Alx Oncology Inc Terapias de combinação para tratamento de câncer
EP4389767A4 (en) 2021-08-17 2026-02-25 Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd Monoclonal antibodies targeting syrup? And their use
US20240010701A1 (en) 2022-06-01 2024-01-11 ALX Oncology Inc. Combination therapies for treating urothelial carcinoma
EP4619435A1 (en) 2022-11-16 2025-09-24 Boehringer Ingelheim International GmbH Predictive efficacy biomarkers for anti-sirpa antibodies
CN115896015B (zh) * 2023-02-08 2023-09-29 上海诚益生物科技有限公司 一种髓系来源抑制性细胞的体外培养方法
CN117054649A (zh) * 2023-08-04 2023-11-14 广州中医药大学第一附属医院 一种慢性萎缩性胃炎向胃癌转化标志物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1048299A1 (en) 1999-04-28 2000-11-02 Faculteit der Geneeskunde van de Vrije Universiteit Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies
JP3936673B2 (ja) 2003-06-02 2007-06-27 国立大学法人群馬大学 Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体
CA2917512C (en) * 2007-10-12 2025-08-05 President And Fellows Of Harvard College VACCINE NANOTECHNOLOGY
PT2242512T (pt) * 2008-01-15 2016-07-18 Univ Leland Stanford Junior Métodos para manipular a fagocitose mediada por cd47
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
EP4311863A3 (en) 2009-05-15 2024-04-10 University Health Network Compositions and methods for treating hematologic cancers targeting the sirp alpha- cd47 interaction
GB201015765D0 (en) * 2010-09-21 2010-10-27 Immatics Biotechnologies Gmbh Use of myeloid cell biomarkers for the diagnosis of cancer
EP3682896A1 (en) * 2011-04-28 2020-07-22 University of Southern California Human myeloid derived suppressor cell cancer markers
US20140242095A1 (en) * 2011-10-19 2014-08-28 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
JP6460796B2 (ja) 2012-01-17 2019-01-30 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 高親和性ｓｉｒｐ−アルファ試薬
JP2016507555A (ja) * 2013-02-06 2016-03-10 インヒブルクス エルピー 血小板非減少性かつ赤血球非減少性ｃｄ４７抗体及びその使用方法
WO2015138600A2 (en) 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies

Also Published As

Publication number Publication date
JP2017538669A (ja) 2017-12-28
DK3783027T3 (da) 2026-02-02
EP3012271A1 (en) 2016-04-27
JP2023078398A (ja) 2023-06-06
EP4691569A3 (en) 2026-04-15
DK3209691T3 (da) 2020-08-24
EP3209691A1 (en) 2017-08-30
HUE050318T2 (hu) 2020-11-30
EP3783027A1 (en) 2021-02-24
US20220281993A1 (en) 2022-09-08
JP2021155432A (ja) 2021-10-07
ES2817074T3 (es) 2021-04-06
US20170247464A1 (en) 2017-08-31
EP4691569A2 (en) 2026-02-11
US20240294659A1 (en) 2024-09-05
PL3209691T3 (pl) 2020-11-16
HK1243428A1 (en) 2018-07-13
WO2016063233A1 (en) 2016-04-28
JP7253008B2 (ja) 2023-04-05
JP6918279B2 (ja) 2021-08-11
CA2964203C (en) 2023-08-22
CA2964203A1 (en) 2016-04-28
ES3060595T3 (en) 2026-03-27
EP3783027B1 (en) 2025-12-03
EP3209691B1 (en) 2020-07-15

Similar Documents

Publication Publication Date Title
HUE050318T2 (hu) Daganatos és fertõzõ betegségek kezelése céljából a mieloidokból nyert szupresszorsejtek megkülönböztetését kiváltó készítmények
IL258955B2 (en) Cancer treatment preparations and methods
ZA201804227B (en) Methods of treating cancer
IL255189A0 (en) Cancer treatment methods
IL251066B (en) Preparations and methods for the treatment of metabolic disorders
ZA201700311B (en) Compositions and methods of use for treating metabolic disorders
IL259040B (en) Use of toll-like receptor 8 agonists for cancer therapy
ZA201703904B (en) Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
IL254842B (en) Therapeutic preparations and methods for use in cancer treatment
IL247981A0 (en) Preparations and methods related to the diagnosis of prostate cancer
PT3283097T (pt) Fsh para tratamento de infertilidade
EP3215140A4 (en) Compositions and methods of diazeniumdiolate-based prodrugs for treating cancer
EP3221351A4 (en) Methods and compositions for cancer treating conditions relating to over expressions of epha2
IL263059A (en) A method for treating cancer by targeting myeloid-derived suppressor cells
IL253847A0 (en) Methods of treating diseases
EP3154952A4 (en) Methods and compositions for treatment of her-positive cancers
IL259781A (en) Uses of pyrimido-pyridazinones to treat cancer
IL252707B (en) Compositions and methods for treating diseases
IL248846A0 (en) Methods and preparations of dezotraline for the treatment of adhd
HK1260504A1 (en) Compositions and methods for treatment of cancer
GB201418268D0 (en) Composition & methods of treatment
GB201418272D0 (en) Composition & methods of treatment